Symptoms may include hives, itching, swelling, dizziness, or difficulty breathing
Although pharmacological compounds aimed at inducing ferroptosis, such as erastin and RSL3, or inhibiting it, such as ferrostatin-1 (fer-1), have demonstrated potential in preclinical studies, their application in clinical settings faces challenges, including off-target effects and limited tissue specificity [2,3,4,5,6]
You should reach out to your healthcare provider if fatigue persists beyond four weeks at a stable dose, worsens significantly, or is accompanied by other concerning symptoms like dizziness, shortness of breath, rapid heartbeat, or signs of depression or anxiety